CD86 and cancer: While freeze/thaw protocol for inducing cell death barely influenced the expression of either marker, PDT-killed cancer cells led to more than 50% MHC-II+ CD80+ CD86+ BM-DCs, almost reaching the numbers obtained with the TLR agonist LPS (Figures 5A,B); similar effects were obtained with another cancer cell line with >60% MHC-II+ CD80+ CD86+ BM-DCs (Supplementary Figure 6).